Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Non-muscular Invasive Bladder Cancer 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Mitomycin 15Gemcitabine 13dodecyl maltoside 5BCG Vaccine 5erdafitinib 4apaziquone 4ALT-803 4Epirubicin 3viscum album peptide 2durvalumab 2VB4-845 2Imiquimod 2Docetaxel 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1pirarubicin 1pembrolizumab 1linrodostat 1hydroxycamptothecinum 1enfortumab vedotin 1catumaxomab 1Water 1Therapeutics 1Therapeutic Uses 1Standard of Care 1Polysorbates 1Photochemotherapy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × Therapeutic Uses × Clear all
NCT06241755 2024-02-05

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Chengdu CoenBiotech Co., Ltd

Phase 3 Recruiting
412 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡